Volume 69, Issue 5, Pages (May 2016)

Slides:

Advertisements

Similar presentations

Charles J. Ryan, M.D., Matthew R. Smith, M.D., Ph.D., Johann S. de Bono, M.B., Ch.B., Ph.D., Arturo Molina, M.D., Christopher J. Logothetis, M.D., Paul.

Advertisements

Volume 69, Issue 5, Pages (May 2016)

Volume 68, Issue 6, Pages (December 2015)

European Urology Focus

Volume 155, Issue 3, Pages (March 1996)

Volume 63, Issue 3, Pages (March 2013)

Bone Scan Index as an Imaging Biomarker in Metastatic Castration-resistant Prostate Cancer: A Multicentre Study Based on Patients Treated with Abiraterone.

Volume 60, Issue 2, Pages (August 2011)

Volume 58, Issue 2, Pages (August 2010)

David Lorente, Karim Fizazi, Christopher Sweeney, Johann S. de Bono

Volume 70, Issue 6, Pages (December 2016)

Volume 68, Issue 6, Pages e129-e131 (December 2015)

Volume 68, Issue 4, Pages (October 2015)

Volume 66, Issue 5, Pages (November 2014)

Heterogeneous Flare in Prostate-specific Membrane Antigen Positron Emission Tomography Tracer Uptake with Initiation of Androgen Pathway Blockade in Metastatic.

Volume 53, Issue 5, Pages (May 2008)

Volume 69, Issue 5, Pages (May 2016)

Volume 51, Issue 4, Pages (April 2007)

Volume 69, Issue 1, Pages (January 2016)

Who Benefits from Neoadjuvant or Adjuvant Hormone Therapy?

Volume 51, Issue 5, Pages (May 2007)

Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration- resistant Prostate Cancer in the Era of Precision Oncology Philipp.

Volume 70, Issue 5, Pages (November 2016)

Volume 71, Issue 2, Pages (February 2017)

Volume 72, Issue 5, Pages (November 2017)

Volume 68, Issue 4, Pages (October 2015)

Volume 65, Issue 5, Pages (May 2014)

Volume 66, Issue 2, Pages (August 2014)

Volume 74, Issue 1, Pages (July 2018)

Volume 74, Issue 4, Pages (October 2018)

Volume 65, Issue 1, Pages (January 2014)

Volume 71, Issue 1, Pages 1-3 (January 2017)

Volume 67, Issue 2, Pages (February 2015)

Volume 70, Issue 4, Pages (October 2016)

Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?

Prostate Cancer Management: What Does the Future Hold?

Volume 66, Issue 3, Pages (September 2014)

Volume 66, Issue 5, Pages (November 2014)

Volume 70, Issue 5, Pages (November 2016)

Volume 70, Issue 4, Pages (October 2016)

Volume 73, Issue 5, Pages (May 2018)

Current Status of Combined Radiation Therapy and Androgen Suppression in Locally Advanced Prostate Cancer: What Is the Way Forward? Michel Bolla European.

Volume 72, Issue 1, Pages (July 2017)

Volume 66, Issue 2, Pages (August 2014)

Volume 74, Issue 2, Pages (August 2018)

RANK Ligand-targeted Therapy: A Novel Approach to Prevent Bone Loss and Fractures in Men with Prostate Cancer Matthew R. Smith European Urology Supplements

Prostate-Specific Antigen Kinetics and Outcomes in Patients with Bone Metastases from Castration-Resistant Prostate Cancer Treated with or Without Zoledronic.

Volume 71, Issue 2, Pages (February 2017)

Volume 52, Issue 6, Pages (December 2007)

Volume 73, Issue 5, Pages (May 2018)

Volume 55, Issue 6, Pages (June 2009)

Volume 71, Issue 5, Pages (May 2017)

Volume 71, Issue 3, Pages (March 2017)

Volume 70, Issue 6, Pages (December 2016)

Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?

Volume 72, Issue 2, Pages (August 2017)

Volume 74, Issue 3, Pages (September 2018)

Volume 71, Issue 4, Pages (April 2017)

Volume 68, Issue 5, Pages (November 2015)

Improving Outcomes in Prostate Cancer: Time to Tackle Bone Disorders

Volume 69, Issue 5, Pages (May 2016)

European Urology Oncology

Axel Heidenreich European Urology Supplements

European Urology Oncology

Volume 53, Issue 6, Pages (June 2008)

Oncoforum Urology: Prostate Cancer 2008 at a Glance

Axel Heidenreich European Urology Supplements

Volume 51, Issue 5, Pages (May 2007)

European Urology Oncology

Abiraterone in “High-” and “Low-risk” Metastatic Hormone-sensitive Prostate Cancer Alex P. Hoyle, Adnan Ali, Nicholas D. James, Adrian Cook, Christopher.

Presentation transcript:

Volume 69, Issue 5, Pages 924-932 (May 2016) Prior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 Studies Joaquim Bellmunt, Thian Kheoh, Margaret K. Yu, Matthew R. Smith, Eric J. Small, Peter F.A. Mulders, Karim Fizazi, Dana E. Rathkopf, Fred Saad, Howard I. Scher, Mary-Ellen Taplin, Ian D. Davis, Dirk Schrijvers, Andrew Protheroe, Arturo Molina, Peter De Porre, Thomas W. Griffin, Johann S. de Bono, Charles J. Ryan, Stéphane Oudard European Urology Volume 69, Issue 5, Pages 924-932 (May 2016) DOI: 10.1016/j.eururo.2015.10.021 Copyright © 2015 European Association of Urology Terms and Conditions

Fig. 1 Consolidated Standards of Reporting Trials diagram for (A) COU-AA-301 and (B) COU-AA-302. AA=abiraterone acetate; GnRH=gonadotropin-releasing hormone; ITT=intention-to-treat; P=prednisone. European Urology 2016 69, 924-932DOI: (10.1016/j.eururo.2015.10.021) Copyright © 2015 European Association of Urology Terms and Conditions

Fig. 2 Radiographic progression-free survival Kaplan-Meier estimates in COU-AA-301 patients with prior endocrine therapy exposure by duration in quartiles for (A) gonadotropin-releasing hormone agonists and (B) androgen receptor antagonists. AA=abiraterone acetate; CI=confidence interval; HR=hazard ratio; P=prednisone; rPFS=radiographic progression-free survival; Q=quartile. European Urology 2016 69, 924-932DOI: (10.1016/j.eururo.2015.10.021) Copyright © 2015 European Association of Urology Terms and Conditions

Fig. 3 Radiographic progression-free survival Kaplan-Meier estimates in COU-AA-302 patients with prior endocrine therapy exposure by duration in quartiles for (A) gonadotropin-releasing hormone agonists and (B) androgen receptor antagonists. AA=abiraterone acetate; CI=confidence interval; HR=hazard ratio; P=prednisone; rPFS=radiographic progression-free survival; Q=quartile. European Urology 2016 69, 924-932DOI: (10.1016/j.eururo.2015.10.021) Copyright © 2015 European Association of Urology Terms and Conditions